Compare ARK Genomic Revolution ETF (ARKG) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Cintas Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Cintas Corporation trades at $180.27 (market cap $71.88B). The key difference: Cintas Corporation pays a 1% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Cintas Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | CTAS | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $226.27 |
52-Week Low | $23.09 | $163.55 |
Market Cap | — | $71.88B |
Enterprise Value | — | $74.62B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Cintas (CTAS) trades at $179.64, up 1.1% on the day, with a bullish technical signal and strong fundamentals including 17.57% net margin and consistent revenue growth to $10.34B in 2025. The stock shows robust cash flow from operations at $2.17B and has beaten earnings estimates in recent quarters. Recent news highlights upcoming Q4 2026 earnings and recognition as a top workplace, supporting positive sentiment.
Outlook remains favorable with a consensus price target of $212.50, though high valuation multiples (P/E 37.9) and competitive pressures pose risks. Earnings growth and market share expansion are key catalysts, but investors should monitor debt levels and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
